HDAC6 and plasma cell myeloma: Because treatment of E.G7-Ova cells with HDAC6 inhibitors modulated the murine MHC-I immunopeptidome, we next determined the effect of HDAC6 inhibitors on the myeloma class I immunopeptidome.